Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders
Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
- Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
- Preclinical data with its first candidate, using ENC-201 in T1D, reported no fibrosis, or immune response, while maintaining cell viability and function.
- “This new financing led by Khosla Ventures, enables us to advance development of our Cell Encapsulation platform, which aims to provide years of therapeutic benefit with a single implant.
- The technology can be used in a variety of different indications, beginning with chronic endocrine disorders,” said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin.